Adjuvant Nivolumab Improves DFS in MIUC After Radical Surgery
CheckMate 274 investigators compared adjuvant nivolumab with placebo (PBO) in patients with MIUC who received cisplatin prior to radical surgery.
Diagnosis & Disease Information
Survival Trends Analysis Shows Significant OS Gains for MIBC, But Not Urothelial Carcinoma
Investigators of this real-world analysis studied survival trends among patients with muscle-invasive bladder cancer (MIBC) and patients with metastatic urothelial carcinoma (UC).
Percent Decline in PSA May Predict Survival in Enzalutamide-Treated nmCRPC
The percent decline and actual decline in PSA levels in men with nonmetastatic castration-resistant prostate cancer treated with androgen deprivation therapy and enzalutamide are associated with the risk for death and metastasis, a study found.
Bone Metastases Predict Worse mUC Immunotherapy Outcomes
The presence of bone metastases is associated with shorter survival among patients who received single-agent immunotherapy for metastatic urothelial carcinoma.
Family History of Hereditary Cancer May Up PCa Progression Risk on Active Surveillance
Even men who test negative for mutations in the BRCA1/2 DNA repair genes may have increased risk for prostate cancer progression when they have certain family history.
Comorbidity Burden Predicts Survival in Renal Cell Carcinoma Cases
As comorbidity burden increases, so does the risk of death among patients with renal cell carcinoma, a study found.
Optimal Sequencing of ADT and RT for Low PSA Prostate Cancer Probed
During the COVID-19 pandemic, neoadjuvant ADT has been used as a way to delay initiation of daily radiation therapy, but it may not be appropriate for all men.
- Loading...
Loading...
Next post in ASCO GU 2021
Loading... 
Loading...